Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


German lung cancer incidence rises in women:

This article was originally published in Clinica

Executive Summary

The incidence of lung cancer in German women has risen dramatically in the last two decades, and while prevention following cutting out or down on tobacco has been successful in men, in women the same cannot be claimed. So says Christa Stegmaier, the head of the epidemiological cancer registry of the state of Saarland. Citing figures that are claimed to be representative for the whole of Germany, she said that lung cancer in Saarland women has risen by 173% in the last 20 years. A quarter of female lung cancer deaths were in the under-60 age bracket. Breast cancer is the leading female cancer in the state. In males, increased screening has seen prostate cancer overtake lung cancer as the leading form of the disease. Several thousand men had opted to take PSA tests under a programme organised by the Homburg Uniclinic, she said.

You may also be interested in...

Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

Covid-19 Scam Complaints Double In A Week, But FTC Enforcement Considers 'Good Faith' Factor

FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.

No Facility Inspections? No Shortage Of Bogus Pandemic Claims Found Online By US Agencies

Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts